bms-790052 and Agammaglobulinemia

bms-790052 has been researched along with Agammaglobulinemia* in 1 studies

Other Studies

1 other study(ies) available for bms-790052 and Agammaglobulinemia

Article	Year
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia. The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:3 Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine	2019

Article

Year

Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia.

The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:3

Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine

2019